Regulus Therapeutics, Inc.
10614 Science Center Drive
San Diego
California
92121
United States
Tel: 858-202-6300
Fax: 858-202-6363
Website: http://www.regulusrx.com/
Email: careers@regulusrx.com
About Regulus Therapeutics, Inc.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.
Regulus is located in La Jolla, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
Regulus Seeks Highly Motivated, Innovative and Passionate Team Members
338 articles about Regulus Therapeutics, Inc.
-
Regulus Therapeutics, Inc. Reports Third Quarter 2013 Financial Results And Recent Highlights
11/14/2013
-
Regulus Therapeutics, Inc. Presents Positive Preclinical Data Demonstrating That microRNA-21 Plays an Important Role in Alport Syndrome
11/8/2013
-
Regulus Therapeutics, Inc. Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
11/7/2013
-
Regulus Therapeutics, Inc. Release: Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
11/4/2013
-
Regulus Therapeutics, Inc. Announces Significant Progress in Strategic Alliance With AstraZeneca PLC and Selection of a New Pre-Clinically Validated microRNA Oncology Target
10/28/2013
-
Regulus Therapeutics, Inc. Reports Second Quarter 2013 Financial Results and Recent Highlights
8/14/2013
-
Regulus Therapeutics, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
8/7/2013
-
Regulus Therapeutics, Inc. Announces Completion of Public Offering and Exercise in Full of Overallotment Option
7/23/2013
-
Regulus Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
7/17/2013
-
Regulus Therapeutics, Inc. Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
6/11/2013
-
Regulus Therapeutics, Inc. to Present at Deutsche Bank 38th Annual Healthcare Conference
5/22/2013
-
Regulus Therapeutics, Inc. Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
5/15/2013
-
Regulus Therapeutics, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
5/8/2013
-
Regulus Therapeutics, Inc. to Present at 12th Annual Needham Healthcare Conference
4/25/2013
-
Regulus Therapeutics, Inc. Appoints William H. Rastetter, Ph.D. to its Board of Directors
4/1/2013
-
Regulus Therapeutics, Inc. to Present at Future Leaders in the Biotech Industry Conference
3/29/2013
-
Regulus Therapeutics, Inc. to Present at Cowen and Company 33rd Annual Healthcare Conference
2/27/2013
-
Regulus Therapeutics, Inc. Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
2/21/2013
-
Regulus Therapeutics, Inc. Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
2/14/2013
-
Regulus Therapeutics, Inc. to Present at Two Upcoming Investor Conferences
2/5/2013